# Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients

> **NCT03149900** · — · COMPLETED · sponsor: **Diamant Thaci** · enrollment: 40 (actual)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **DRUG:** Secukinumab

## Key facts

- **NCT ID:** NCT03149900
- **Lead sponsor:** Diamant Thaci
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2019-07-25
- **Final completion:** 2019-07-25
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2019-08-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03149900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03149900, "Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03149900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*